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NBD-556 is a class of HIV-1 entry inhibitors that binds HIV-1 surface glycoprotein gp120 and induces confor-
mational changes, which mimic those caused by CD4 binding. Here, Madani et al. (2008) show that NBD-556
binds to the highly conserved ‘‘Phe-43 cavity’’ on gp120.HIV-1 entry into cells is mediated by enve-
lope spikes on the surface of viral parti-
cles. These trimeric envelope glycopro-
teins consist of three transmembrane
gp41 and three surface gp120 molecules.
Gp120 interacts sequentially with CD4
and a coreceptor on the cell surface to
trigger fusion of viral and cell membranes
and entry of the virus core into the cyto-
plasm. In the unliganded state, gp120 is
believed to be relatively disordered and
to move through various conformations
(Xiang et al., 2002). Binding to CD4 in-
duces extensive conformational changes
that bring together inner and outer do-
mains of gp120 and form a connecting
bridging sheet comprising of four anti-
parallel b strands, (Figure 1A). This pro-
cess fixes gp120 into a CD4-bound
form that is competent for binding the
CCR5 or CXCR4 coreceptor. When the
first crystal structure of gp120 complexed
to CD4 was published (Kwong et al.,
1998), a very interesting cavity was appar-
ent in gp120 at the interface with CD4.
This cavity was at the nexus of the three
gp120 domains brought together by
CD4 and was penetrated by the phenolic
ring of phenylalanine 43 (Phe-43) of CD4
(Figure 1B). The Phe-43 cavity and proxi-
mal rim residues represent one of the
fewwell-conserved surfaces on the trimer
that is readily accessible to small mole-
cules. This site thus represents a very at-
tractive target for drug development.
In this issue, Madani et al. (2008) pro-
vide evidence that a small molecule called
NBD-556 (Figure 1C) can penetrate deep
into the Phe-43 cavity, interacting with
the surrounding conserved gp120 resi-
dues (Figure 1D). NBD-556 and the re-
lated NBD-557 had previously been iden-
tified from a screen of a library of small
molecules for their capacity to inhibit
HIV-1-induced syncytia in a cell–cellfusion assay (Zhao et al., 2005). These
molecules were then shown to be able
to inhibit infection of CCR5- and CXCR4-
using primary HIV-1 isolates representing
diverse clades. In a subsequent report,
Scho¨n et al. (2008) showed that NBD-
556 binding to gp120 resulted in large in-
creases in enthalpy and corresponding
decreases in entropy, reminiscent of the
thermodynamic changes that occur
when CD4 binds gp120. Remarkably,
these thermodynamic shifts result from
the capacity of NBD-556 to induce con-
formational changes in gp120, similar to
those induced by CD4, that result in the
exposure of the coreceptor binding site
(Scho¨n et al., 2006). The NBD-556 in-
duced changes are not as extensive as
those induced by CD4, with approxi-
mately 67 gp120 residues estimated to
be structured compared to 130 by CD4
(Scho¨n et al., 2006). NBD-556 conferred
enhanced binding of the monoclonal anti-
body (Mab) 17b, which usually binds
CD4-induced epitopes on gp120, and in-
duced low but significant levels of infec-
tion via CCR5 in the absence of CD4.
These observations indicate that NBD-
556 has induced the assembly and expo-
sure of the coreceptor binding site. Eluci-
dation of the precise gp120 conformation
induced by NBD-556 will require struc-
tural information on the drug bound
gp120.
Madani et al. (2008) used different mo-
lecular modeling approaches to predict
that NBD-556 penetrates deep into the
Phe-43 cavity, leading with its chloro-
phenyl ring and entering 6.5A˚ deeper in
comparison to Phe-43 of CD4 (Figures
1B and 1D). The model predicts that the
chloro-phenyl ring of NBD-556 partici-
pates in aromatic-aromatic stacking inter-
actions with gp120 residues Trp-447,
Phe-382, and Trp-112, while the NBD-Structure 16, November 12, 2008 ª556 oxalamide forms hydrogen bonds
with gp120 backbone carbonyls in the
neck of the cavity. These interactions are
likely to stabilize the NBD-556-gp120
complex.
The authors tested this model using
various gp120 mutants and different
NBD-556 analogs. The most telling
gp120 mutant S375W, where the side
chain of tryptophan is predicted to fill the
Phe-43 cavity, completely abrogated
NBD-557 binding and activation of
gp120. Other substitutions of gp120 resi-
dues that line the cavity or surround the
cavity’s vestibule mainly decrease NBD-
556 binding and activation of gp120,
although S375A conferred enhanced
activation. These observations strongly
support a role for the cavity and proximal
sites on the rim as critical targets for
NBD-556.
Investigation of NBD-556 analogs sup-
ported the model’s prediction that the
phenyl ring and oxalamide linker were in-
volved in gp120 binding and CD4 mim-
icry. The different analogs varied in their
affinity for gp120 and ability to induce
the conformational changes that create
the CCR5 binding site and enable CD4-
independent infection. Overall, a combi-
nation of high affinity for gp120 in tandem
with the capacity to induce conforma-
tional rearrangements was required for
the analogs to inhibit infection of CD4+
cells.
The ability to interact with highly con-
served residues near or within the Phe-
43 cavity make NBD-556 and related
molecules excellent lead compounds for
further development of derivatives that
will bind gp120 with higher affinity and in-
hibit infection in the nanomolar range. The
authors themselves suggest that alter-
ations focused on the piperidine ring
would be the next to be pursued.2008 Elsevier Ltd All rights reserved 1603
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prospects and potential prob-
lems associated with this ap-
proach? How easy would it
be for HIV-1 to escape such
a drug? Several gp120 mu-
tants described here with
changes in residues that con-
tact the Phe-43 cavity, lost
binding to NBD-556. These
mutants suggest that escape
may occur readily. However,
some of these substitutions
seem to favor a gp120 con-
formation closer to the more
open CD4- bound state and
may render the envelope
more sensitive to neutralizing
antibodies (Xiang et al.,
2002). Overall, HIV-1 escape
from NBD-556 and other ana-
logs is difficult to predict and
will need to be tested empiri-
cally. Regardless, any thera-
peutic strategy would inevita-
bly involve the use of drugs in
combinations, greatly reduc-
ing the likelihood of escape
mutants emerging in vivo.
For example, combinationwith other entry inhibitors would greatly
increase the constraints on fusion and
entry.
Are there HIV-1 variants already out
there that are naturally resistant to NBD-
556? In the original description of NBD-
556 (Zhao et al., 2005), HIV-1 strains
from diverse clades were tested and all
were sensitive to inhibition, albeit in the
micromolar range. This observation raises
the promise that more potent inhibitors of
this class will have wide coverage of di-
verse HIV-1s. A potential bonus of NBD-
556 and similarly active molecules is that
they may also confer enhanced sensitivity
to neutralizing antibodies by inducing the
exposure of critical epitopes on the
CD4- and coreceptor- binding sites. How-
ever, if NBD-556 and similar drugs induce
infection of CD4-negative cells via direct
interactions with CCR5 (as shown in the
present study), will this be a problem for
in vivo use? An expansion of HIV-1 into
cell types that lack CD4 could potentially
greatly exacerbate pathogenesis in vivo.1604 Structure 16, November 12, 2008 ª200However, CD4-independent infection
usually relies on levels of cell surface
CCR5 on test cell lines that are much
higher than the typical levels of CCR5 ex-
pression in vivo (Bhattacharya et al., 2003)
and this may not be a serious issue. Nev-
ertheless, it is possible that small mole-
cules like NBD-556 (at suboptimal levels)
may enhance infection of CD4+ cells by
facilitating conformational changes and
CCR5 interactions in envelope spikes
not bound to CD4, thus increasing the
number of fusion- active envelope spikes
on a virus particle at the cell surface.
Whether this is a genuine possibility is
currently unclear. Investigation of future,
more potent NBD-556 derivatives in the
SHIV rhesusmacaquemodel may help re-
solve whether this and other issues that
are a concern for therapeutic use in vivo.
Finally, we need to return to the original
question. How attractive a target is the
Phe-43 cavity for drug development?
The Phe-43 cavity is formed after confor-
mational changes are induced in gp1208 Elsevier Ltd All rights reservedand represents a conforma-
tion of gp120 that is an inter-
mediate in the HIV-1 entry
process. One particular
NBD-556 analog (JRC-II-
192) bound gp120 with high
affinity and competed with
NBD-556 for binding, but
induced less significant con-
formational changes. Intui-
tively, molecules that don’t
induce gp120 to enter the
pathway of conformational
shifts that eventually lead to
fusion ought to be superior
or preferred inhibitors. How-
ever, only NBD-556 and ana-
logs that combined a high
binding affinity and induction
of gp120 conformational
changes could specifically
inhibit HIV-1 infection. The ex-
planation behind these obser-
vations is currently obscure.
In summary, NBD-556 rep-
resents a novel class of HIV-1
inhibitors that target the Phe-
43 cavity on gp120, a highly
conserved and accessible
site for small antiviral mole-cules. The challenge now is to rationally
design a new generation of inhibitors tar-
geted to this and proximal sites that block
CD4 binding and confer more potent
inhibition of HIV-1 infection.
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Virology 339, 213–225.Figure 1. NBD-556 and CD4 Binding to the HIV-1 gp120 Envelope
Glycoprotein
(A) Conformational changes in the HIV-1 envelope induced by CD4 that form
a binding site for the coreceptor.
(B) The Phe-43 cavity of gp120 is penetrated by the phenyl ring of CD4 residue,
Phe-43.
(C) The chemical structure of NBD-556.
(D) NBD-556 is predicted to penetrate deeper into the Phe-43 cavity compared
to CD4.
Figures 1B and D were prepared by Corcoran Graphics Inc.
